September 10, 2026 (View All Issues)
ASCENT-04 Exploratory Analysis: Sacituzumab Govitecan Plus Pembrolizumab Improves PFS2, Delays Next Treatment
First-line treatment with the antibody-drug conjugate sacituzumab govitecan-hziy plus pembrolizumab led to a longer progression-free survival after next line of treatment—ie, progression-free survival–2 (PFS2)—than chemotherapy plus pembrolizumab in patients with previously untreated,...
Long-Term Trial Supports Selective Use of Extended Pelvic Lymph Node Dissection in High-Grade Prostate Cancer
Extended pelvic lymph node dissection has long been used during radical prostatectomy to improve staging in men with higher-risk prostate cancer. Whether the more extensive operation also improves cancer outcomes has been less clear.
New long-term randomized data presented at the 2026 American...
The Mid-Career Oncologist in LMIC Regions: Navigating Disparities, Avoiding Burnout, and Delivering Optimal Care
To be a mid-career oncologist is to occupy an emotionally and physically taxing space within a trying clinical environment. We may be 10 years and beyond our post-training. We are no longer trainees who may be protected by institutional shields, nor are we established senior department heads with ...
Additional Safety Analysis of DESTINY-Breast05: What Did It Show?
An additional safety analysis of the global phase III DESTINY-Breast05 trial evaluating the HER2-directed antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) has further established the pulmonary safety profile of T-DXd with radiotherapy, according to Michael Untch, MD, PhD, of Helios...
Structured Exercise After Adjuvant Chemotherapy for Colon Cancer Improves Survival and Saves Costs
A structured exercise program after adjuvant chemotherapy for colon cancer improved survival and saved money.
In a preplanned cost-utility analysis of the phase III CHALLENGE trial, presented at the 2026 ASCO Annual Meeting1 and published simultaneously in the Journal of Clinical Oncology,2 the...
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) recently approved daraxonrasib, (Rasonque), a multiselective RAS(ON) inhibitor, for treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
...
ASCO Remembers Dr. Harold P. Freeman, Preeminent Health Equity Expert and Pioneer of Patient Navigation
ASCO joins the oncology community in mourning the death of Harold P. Freeman, MD, a world-renowned expert on and advocate for health equity and the pioneer of patient navigation services in oncology. Dr. Freeman passed away on August 11, 2026; he was 93.
After completing medical training at...
ASCO Remembers Supportive Care and Symptom Management Pioneer Gary R. Morrow, PhD, MS
ASCO joins the oncology community in mourning the death of Gary R. Morrow, PhD, MS, who passed away on July 7, 2026; Dr. Morrow was 82.
Dr. Morrow was a pioneer in the field of supportive care, and his research on the potentially debilitating side effects of cancer treatment, including nausea,...
‘Save Research’ Campaign Champions Federal Funding
ASCO members are leading the way to make sure Congress understands the critical importance of federal cancer research funding before the September 30 federal funding deadline.
“The People Behind the Progress,” an ASCO social media series, features members sharing how federal cancer research has...
Envafolimab Regimen Improves Pathologic Complete Response in MSS Locally Advanced Rectal Cancer
Adding the subcutaneous PD-L1 blocker envafolimab to short-course radiotherapy and CAPEOX (capecitabine and oxaliplatin) improved pathologic complete response (pCR) without a clear safety or surgical feasibility penalty in patients with microsatellite-stable (MSS) locally advanced rectal cancer,...
GLP-1 Receptor Agonists Linked to Lower Colorectal Cancer Risk in Patients With IBD
A large retrospective cohort study found that GLP-1 receptor agonist use was associated with significantly lower 5-year rates of colorectal cancer among patients with inflammatory bowel disease (IBD). The research was highlighted in a press briefing ahead of the 2026 ASCO Breakthrough Meeting,1...
First-in-Class Bispecific ADC Shows Activity in Relapsed Extensive-Stage Small Cell Lung Cancer
In a phase Ib study published in the Journal of Clinical Oncology, Zhao et al found that the first-in-class bispecific antibody-drug conjugate (ADC) izalontamab brengitecan (iza-bren, BL-B01D1), which targets EGFR and HER3, demonstrated antitumor activity in patients with relapsed extensive-stage...
cfDNA Fragmentomics Plus Methylation Analysis May Improve Detection of Precancerous Colorectal Lesions
A blood-based assay combining cell-free DNA (cfDNA) fragmentomics with droplet digital PCR–based methylation analysis improved detection of early-stage colorectal cancer (CRC) and precancerous lesions, according to findings presented at the 2026 ASCO Breakthrough meeting in Singapore.
In this...
The 2026 ASCO Annual Meeting Geriatric Oncology Update: The Next Challenge Is Implementation
For more than a decade, geriatric oncology has evolved from a niche discipline into an evidence-based component of high-quality cancer care. Landmark randomized trials, including the Geriatric Assessment for Patients 70 Years and Older Starting Cancer Treatment (GAP70+) trial,1 the Geriatric...
20th Annual Award for Leadership in Personalized Medicine
The Personalized Medicine Coalition (PMC), a nonprofit organization dedicated to advancing personalized medicine, recently announced that physician-scientist Norman E. “Ned” Sharpless, MD, has been selected as the recipient of the 20th Annual Award for Leadership in Personalized Medicine,...
U.S. News & World Report Announces 2026–2027 Best Cancer Hospitals
U.S. News & World Report today released the 2026–2027 edition of Best Hospitals. Now in its 37th year, the annual study helps patients and their families make informed, data-driven health-care decisions in consultation with their medical providers and care teams.
The top 10 hospitals for the...
Dr. Gary R. Morrow, a Pioneer in Cancer Research, Dies at 82
Gary R. Morrow, PhD, MS, died on July 7, 2026, at age 82, from complications due to pneumonia and a 16-year history of prostate cancer, according to an obituary shared by his family.
Over nearly 5 decades at the University of Rochester Wilmot Cancer Institute, Dr. Morrow brought in $100 million...
Surviving Cancer Put Me On a Career Path in Cancer Research
I was just 24 and in seemingly perfect health when I began experiencing unexplained abdominal pain so excruciating, even daily doses of pain medication failed to provide relief. I was a senior in college and had enrolled in a summer internship program at the University of California, Davis, when my ...
